Alexander Shneider: Elenagen Combination Extends Survival in Ovarian Cancer

February 25, 2026 Alexander Shneider: Elenagen Combination Extends Survival in Ovarian Cancer This article was originally published in OncoDaily Alexander Shneider: Elenagen Combination Extends Survival in Ovarian Cancer Alexander Shneider , founder and CEO of CureLab Oncology, Inc. shared a post on LinkedIn : “We are honored to see our recent clinical data featured in EMJ Oncology . For patients with platinum‑resistant ovarian cancer – one of the most challenging diagnoses in oncology – these findings point toward what may become a meaningful paradigm shift. Clinical Highlights: Doubling of Median Survival: 13 → 25+ months in this study Zero Added Toxicity : A rare safety profile that supports the body’s biology rather than intensifying chemotherapy A New Class of Therapy : Reinforcing Elenagen’s unique role in modulating chronic inflammation and reshaping the tumor microenvironment As we move toward our US/Global Phase II/III trials, this external validation underscores the life‑saving potential of our platform. The Path Forward: We hope this recognition – alongside dozens of recent features in English, Spanish, and Portuguese – encourages future partners and investors to engage with the speed required to bring this potential breakthrough to clinicians and patients.” Share Related posts September 3, 2026 Hormone-resistant prostate and breast cancers added to clinical study based on encouraging preliminary results Read more Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.

The release as fetched from its publisher. curelaboncology.com ↗